AKBA Valuation

Akebia Therapeutics Inc

Add to Watchlist

Advanced Chart

2.850

-0.1(-3.390%)1D

Overview
Forecast
Valuation
Earnings

AKBA Relative Valuation

AKBA's fair value is calculated using relative valuation, based on historical P/E and P/S ranges and their premiums/discounts relative to a competitor average, adjusted by weights. If the market price exceeds this fair value range, AKBA is overvalued; if below, it's undervalued.

Historical Valuation

Akebia Therapeutics Inc (AKBA) is now in the Fair zone, suggesting that its current forward PS ratio of 0.00 is considered Fairly compared with the five-year average of -7.58. The fair price of Akebia Therapeutics Inc (AKBA) is between NaN to NaN according to relative valuation methord.

Relative Value

Fair Zone

NaN-NaN

Current Price：2.85

Fair

-59.00

Trailing

Forward

0.00

EV/EBITDA

Akebia Therapeutics Inc. (AKBA) has a current EV/EBITDA of 0.00. The 5-year average EV/EBITDA is -1.06. The thresholds are as follows: Strongly Undervalued below -3.87, Undervalued between -3.87 and -2.46, Fairly Valued between 0.35 and -2.46, Overvalued between 0.35 and 1.75, and Strongly Overvalued above 1.75. The current Forward EV/EBITDA of 0.00 falls within the Historic Trend Line -Fairly Valued range.

49.42

EV/EBIT

Akebia Therapeutics Inc. (AKBA) has a current EV/EBIT of 49.42. The 5-year average EV/EBIT is 4.78. The thresholds are as follows: Strongly Undervalued below -169.36, Undervalued between -169.36 and -82.29, Fairly Valued between 91.84 and -82.29, Overvalued between 91.84 and 178.91, and Strongly Overvalued above 178.91. The current Forward EV/EBIT of 49.42 falls within the Historic Trend Line -Fairly Valued range.

3.22

Akebia Therapeutics Inc. (AKBA) has a current PS of 3.22. The 5-year average PS is 1.74. The thresholds are as follows: Strongly Undervalued below -0.29, Undervalued between -0.29 and 0.73, Fairly Valued between 2.76 and 0.73, Overvalued between 2.76 and 3.77, and Strongly Overvalued above 3.77. The current Forward PS of 3.22 falls within the Overvalued range.

-31.96

P/OCF

Akebia Therapeutics Inc. (AKBA) has a current P/OCF of -31.96. The 5-year average P/OCF is -6.49. The thresholds are as follows: Strongly Undervalued below -49.87, Undervalued between -49.87 and -28.18, Fairly Valued between 15.21 and -28.18, Overvalued between 15.21 and 36.90, and Strongly Overvalued above 36.90. The current Forward P/OCF of -31.96 falls within the Undervalued range.

128.42

P/FCF

Akebia Therapeutics Inc. (AKBA) has a current P/FCF of 128.42. The 5-year average P/FCF is 4.11. The thresholds are as follows: Strongly Undervalued below -65.21, Undervalued between -65.21 and -30.55, Fairly Valued between 38.78 and -30.55, Overvalued between 38.78 and 73.44, and Strongly Overvalued above 73.44. The current Forward P/FCF of 128.42 falls within the Strongly Overvalued range.

Akebia Therapeutics Inc (AKBA) has a current Price-to-Book (P/B) ratio of 26.55. Compared to its 3-year average P/B ratio of 0.86 , the current P/B ratio is approximately 2971.41% higher. Relative to its 5-year average P/B ratio of 1.62, the current P/B ratio is about 1542.75% higher. Akebia Therapeutics Inc (AKBA) has a Forward Free Cash Flow (FCF) yield of approximately 0.00%. Compared to its 3-year average FCF yield of -28.97%, the current FCF yield is approximately -100.00% lower. Relative to its 5-year average FCF yield of -55.49% , the current FCF yield is about -100.00% lower.

26.55

P/B

Median3y

0.86

Median5y

1.62

-0.32

FCF Yield

Median3y

-28.97

Median5y

-55.49

Competitors Valuation Multiple

The average P/S ratio for AKBA's competitors is 0.00, providing a benchmark for relative valuation. Akebia Therapeutics Inc Corp (AKBA) exhibits a P/S ratio of , which is NaN% above the industry average. Given its robust revenue growth of 43.13%, this premium appears sustainable.

P/S

P/E

EV/EBITDA

EV/EBIT

P/S

Revenue Growth

Market Cap

AKBA.O

Akebia Therapeutics Inc

Olema Pharmaceuticals Inc

Loss

716.54M

TBPH.O

Theravance Biopharma Inc

Aquestive Therapeutics Inc

Performance Decomposition

Market capitalization of AKBA increased by 77.71% over the past 1 year. The primary factor behind the change was an decrease in P/E Change from -7.48 to -17.70.

The secondary factor is the Revenue Growth, contributed 43.13%to the performance.

Overall, the performance of AKBA in the past 1 year is driven by P/E Change. Which is more unsustainable.

43.13%

43.65M → 62.47M

Revenue Growth

-102.03%

-19.66 → 0.40

Margin Expansion

136.61%

-7.48 → -17.70

P/E Change

77.71%